LUNGLUNGHealthcare · Medical Devices

LUNG Stock Forecast: Pulmonx Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.57
−6.20% on the day

The 6 Wall Street analysts covering Pulmonx Corp. hold a median 12-month price target of $4 — +55.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$111.9M
Ticker Nerd rank
87/ 100
Median analyst target
$4.00
Analysts covering
6
Revenue$22.8M−4.6% y/y
Operating income−$9.1M
Net income−$10.1M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.1%
1M
+41.2%
YTD
+16.3%
1Y
+96.2%
From 52W high
−18.8%
From 52W low
+119.7%
$1.17
$3.17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pulmonx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
87/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
90
Growth
87
Accruals
84
Momentum
68
Quality
50
Value
47
Issuance
47
Volatility
18

Revisions (90): Analysts have, on balance, been raising their forecasts.

Volatility (18): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LUNG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LUNG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26LUNGHigh $7.00Median $4.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
4
Buy
2
Hold
0
Sell
$2.50
Low
$4.00
Median
$7.00
High

The green dot is the last close — the median target sits +55.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Oct 2026StifelMaintainsBuy$2.50 → $4.00
30 Apr 2026D. Boral CapitalMaintainsBuy$14
5 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026D. Boral CapitalMaintainsBuy—
20 Feb 2026D. Boral CapitalMaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025Lake StreetMaintainsBuy—
8 Sept 2025D. Boral CapitalMaintainsBuy—
1 Aug 2025Wells FargoMaintainsEqual-Weight—
31 July 2025D. Boral CapitalMaintainsBuy—
31 July 2025Lake StreetMaintainsBuy—
31 July 2025Piper SandlerDowngradeNeutral—
31 July 2025StifelMaintainsBuy—
22 May 2025CitigroupMaintainsNeutral—
1 May 2025Canaccord GenuityMaintainsBuy—
1 May 2025D. Boral CapitalMaintainsBuy—
1 May 2025Piper SandlerReiteratesOverweight—
11 Mar 2025D. Boral CapitalMaintainsBuy—
10 Mar 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LUNG.

Market Radar

This page is one stock. Monday covers all of them.

LUNG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LUNG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pulmonx Corp. returned +96.2% against +6.9% for the S&P 500, dividends included.

LUNG vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26LUNGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LUNG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.3×

Cheaper than 60% of US stocks

Price / book
3.3×

Cheaper than 28% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
78.0%

Higher than 89% of US stocks

Operating margin
−44.4%

Higher than 19% of US stocks

Net margin
—
Returns & dividend
Return on equity
−90.3%

Higher than 15% of US stocks

Return on assets
−19.8%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pulmonx Corp. has a market value of $111.9M and an enterprise value of $115.6M.

  • Revenue in the twelve months to 30 June 2026: $87.4M. The latest quarter shrank 4.6% year on year.

  • Net income over the same four quarters: −$48.1M, a −55.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.16.

  • Free cash flow in the twelve months to 30 June 2026: −$30.7M.

  • Shares outstanding: 42.9M.

  • Pulmonx Corp. employs 296 people — $295K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

LUNG and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LUNGPulmonx Corp.$111.9M87
APYXApyx Medical Corp.$101.1M76
STIMNeuronetics, Inc.$95.2M64
QTRXQuanterix Corp.$92.3M53
CATXPerspective Therapeutics, Inc.$91.0M11
TLSITriSalus Life Sciences, Inc.$138.8M34
INGNInogen, Inc.$144.3M77

Take a look at LUNG’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulmonx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LUNG

What is the LUNG stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Pulmonx Corp. have a median 12-month price target of $4, with estimates ranging from $2.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LUNG stock a buy right now?

Of the 6 analysts covering Pulmonx Corp., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmonx Corp. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LUNG?

As at 21 Nov 2026, Pulmonx Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (90 of 100).

Will LUNG stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +55.6% from the last close, and Ticker Nerd's factor model ranks Pulmonx Corp. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LUNG stock forecast for 2030?

No analyst covering Pulmonx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUNG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $7 over the next 12 months.

How has LUNG stock performed over the past year?

Pulmonx Corp. returned +96.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulmonx Corp. do?

Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery.

Company

About Pulmonx Corp.

Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery. Pulmonx also provides the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which support patient evaluation, treatment planning, and clinical decision-making. Its products are used primarily by hospitals and specialty pulmonary centers within interventional pulmonology. Pulmonx serves a global clinical market and positions its portfolio around evidence-based tools that help physicians identify appropriate patients and deliver targeted lung-volume reduction therapy.

CEO Mr. Glendon E. French · 296 employees · United States · https://www.pulmonx.com